Skip to main content
. Author manuscript; available in PMC: 2009 May 1.
Published in final edited form as: Neurochem Int. 2007 Nov 26;52(6):1068–1075. doi: 10.1016/j.neuint.2007.11.006

Figure 4.

Figure 4

This graphic depicts results of in vitro bladder strip contractility experiments in spinal cord injured bladders injected with bovine serum albumin or BoNT-A [SCI (n=5), and SCI-BTX (n=6), respectively). Figure 4A demonstrates the mean contractile amplitude standardized to the cross-sectional area of each bladder strip during non-fatigue stimulation (i.e. point A0 defined in figure 1). BoNT-A treatment had no effect on the baseline contractile amplitude of spinal cord injured bladder strips. Figure 4B shows the mean inhibitory effect of atropine (1µM) on contractile amplitude during non-fatigue stimulation (i.e. point A3 defined in figure 1). Atropine had a significantly greater inhibitory effect in spinal cord injured bladders treated with BoNT-A. *denotes p<0.05 between SCI and SCI-BTX groups using the two-tailed unpaired t-test.